Business Responsibility & Sustainability Report

MARKSANS PHARMA LIMITED

SECTION A: GENERAL DISCLOSURES

Details of the listed entity

Corporate Identity Number (CIN) of the Listed Entity

L24110MH1992PLC066364

Name of the Listed Entity

MARKSANS PHARMA LIMITED

Date of Incorporation

16-04-1992

Registered office address

11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai- 400053

Corporate address

11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai- 400053

E-mail

companysecretary@marksanspharma.com

Telephone

(022) 40012000

Website

www.marksanspharma.com

Financial year for which reporting is being done

Start date

End date

Current Financial Year

01-04-2023

31-03-2024

Previous Financial Year

01-04-2022

31-03-2023

Prior to Previous Financial year

01-04-2021

31-03-2022

Name of the Stock Exchange(s) where shares are listed

Details of the Stock Exchanges
Sr. No.	Name of the Stock exchange	Description of other stock exchange	Name of the Country
1	BSE
2	NSE

Paid-up Capital (In Rs.)

45,31,63,746

Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report

Name

Harshavardhan Panigrahi

Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together).

Standalone basis

Whether the company has mandatorily undertaken reasonable assurance of the BRSR Core?

false

II.

Products/services

Details of business activities (accounting for 90% of the turnover)

Details of business activities (accounting for 90% of the turnover)
Sr. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	Manufacturing	Pharmaceutical Formulation	100.00

Products/Services sold by the entity (accounting for 90% of the entity's Turnover)

Products/Services sold by the entity (accounting for 90% of the entity's Turnover)
Sr. No.	Product/Service	NIC Code	% of total Turnover contributed
1	Solid Orals, Tablets and Capsules (including Soft Gelatin Capsules)	2100	100.00

NIC Code list link:

https://www.ncs.gov.in/Documents/NIC_Sector.pdf

III.

Operations

Number of locations where plants and/or operations/offices of the entity are situated

Location

Number of plants

Number of offices

Total

National

International

Markets served by the entity

Number of locations

Locations

Number

National (No. of States)

International (No. of Countries)

What is the contribution of exports as a percentage of the total turnover of the entity?

100.00

A brief on types of customers

1. Retail Chains 2. Pharmacy Stores 3. Hospitals 4. Institutions

IV.

Employees

Details as at the end of Financial Year

Employees and workers (including differently abled)

Sr. No.

Particulars

Total(A)

Male

Female

Other

No.(B)

% (B/A)

No.(C)

% (C/A)

No.(H)

% (H/A)

EMPLOYEES

Permanent (D)

815

704

86.39

111

13.62

0.00

Other than permanent (E)

0.00

Total employees (D + E)

815

704

86.39

111

13.62

0.00

WORKERS

Permanent (F)

326

100.00

0.00

Other than permanent (G)

277

180

64.99

35.02

0.00

Total workers (F + G)

603

506

83.92

16.09

0.00

Differently abled Employees and workers:

Sr. No.

Particulars

Total(A)

Male

Female

Other

No.(B)

% (B/A)

No.(C)

% (C/A)

No.(H)

% (H/A)

DIFFERENTLY ABLED EMPLOYEES

Permanent (D)

0.00

Other than permanent (E)

0.00

Total differently abled employees (D + E)

0.00

DIFFERENTLY ABLED WORKERS

Permanent (F)

0.00

Other than permanent (G)

0.00

Total differently abled workers (F + G)

0.00

Participation/Inclusion/Representation of women

Total (A)

No. and percentage of Females

No. (B)

% (B/A)

Board of Directors

25.00

Key Management Personnel

0.00

Turnover rate for permanent employees and workers (Disclose trends for the past 3 years)

Turnover rate in current FY (2023-24)

Turnover rate in previous FY (2022-23)

Turnover rate in the year prior to the previous FY (2021-22)

Male

Female

Other

Total

Male

Female

Other

Total

Male

Female

Other

Total

Permanent Employees

15.00

3.00

0.00

18.00

12.00

2.00

0.00

14.00

15.00

1.00

0.00

16.00

Permanent Workers

12.00

0.00

12.00

10.00

3.00

0.00

13.00

12.00

2.00

0.00

14.00

Holding, Subsidiary and Associate Companies (including joint Ventures)

(a) Names of holding / subsidiary / associate companies / joint ventures

Holding, Subsidiary and Associate Companies (including joint Ventures)
Sr.No.	Name of the holding / subsidiary/associate companies/joint ventures (A)	Indicate whether holding/Subsidiary/Associate/Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1	Marksans Pharma (UK) Ltd	Subsidiary	100.00	false
2	Marksans Pharma Inc.	Subsidiary	100.00	false
3	Nova Pharmaceuticals Australasia Pty Ltd.	Subsidiary	60.00	false
4	Nova Pharmaceuticals Ltd.	Subsidiary	100.00	false
5	Marksans Pharma GmbH	Subsidiary	100.00	false
6	Access Healthcare for Medical Products L.L.C	Subsidiary	100.00	false
7	Marksans Holdings Limited	Subsidiary	100.00	false
8	Relonchem Limited	Subsidiary	100.00	false
9	Time Cap Laboratories Inc.	Subsidiary	100.00	false
10	Bell Sons & Co. (Druggists) Limited	Subsidiary	100.00	false
11	Marise Ann Inc.	Subsidiary	100.00	false
12	Marksans Realty LLC	Subsidiary	100.00	false
13	Custom Coatings Inc.	Subsidiary	100.00	false

VI.

CSR Details

(i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No)

true

(ii) Turnover (in Rs.)

6,55,20,32,928

(iii) Net worth (in Rs.)

11,11,32,07,852

VII.

Transparency and Disclosures Compliances

Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct

Stakeholder group from whom complaint is received

Grievance Redressal Mechanism in Place (Yes/No/NA)

(If Yes, then provide web-link for grievance redress policy)

FY (2023-24)

PY (2022-23)

(If NA, then provide the reason)

Number of complaints filed during the year

Number of complaints pending resolution at close of the year

Remarks

Number of complaints filed during the year

Number of complaints pending resolution at close of the year

Remarks

Communities

Yes

h t t p s : / / w w w . marksanspharma.com/csr. Html

NIL

Investors (other than shareholders)

Yes

h t t p s : / / w w w . marksanspharma.com/ adverse-event.html

NIL

Shareholders

Yes

https://www.marksanspharma. com/investor-contact.html

NIL

One Compliant was received in Q3 which has been resolved

Employees and workers

Yes

https://www.marksanspharma. com/pdf/Code-of-Conduct.pdf

NIL

Customers

Yes

https://www.marksanspharma. com/quality-policy.html

NIL

Value Chain Partners

Yes

https://www.marksanspharma. com/adverse-event.html

NIL

Details of Other Stakeholder Group
Sr. No.	Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No/NA)	(If Yes, then provide web-link for grievance redress policy)	FY (2023-24)			PY (2022-23)			(If NA, then provide the reason)
				Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks

Overview of the entity's material responsible business conduct issues

Overview of the entity's material responsible business conduct issues
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications, as per the following format
Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1	Governance	R&O	Risk Companies that do not have effective corporate governance practices are often prone to Fraud and mismanagement. Poor corporate governance practices weaken Company's ability to capitalise business opportunities, thereby resulting in financial losses. This may further lead to a loss of shareholder confidence and trust as well as increased Government/regulatory oversight/ sanctions/ fines Opportunity Strong corporate governance will result in increased stakeholder confidence and trust, higher ESG ratings, and stronger brand equity	Implementing checks and balances to have appropriate controls and oversight responsibilities. Instituting a Board and Committee structure and implementing board effectiveness measures in line with the stakeholders' long term interests.	Positive Implications
2	Business Ethics	R	Non-adherence to and non-compliance with ethical standards can put Pharma companies at risk of legal fines, penalties, damaged reputation, business disruption, regulatory sanctions and erosion of trust and market capital	Establishing processes and controls to strengthen Company's Compliance with the Code of Conduct as well as applicable policies, followed by an independent audit. Institutionalising effective whistleblower and grievance Redressal mechanisms. Creating a culture of following the highest standards of governance.	Negative Implications
3	Talent attraction and retention	R	The ability to attract and retain the right technical talent with required skill sets is a challenge. The industry is highly knowledge-driven, technology-based and heavily reliant on specialist individuals.	We embed workforce planning into our operations strategy, and this helps in fostering internal mobility for well suited roles, enhancing people productivity and containing staff costs. We are maintaining an internal pipeline of qualified and experienced critical talent, particularly in specialised fields, to deliver our business priorities.	Negative Implications
4	Regulatory Compliance	R	Regulatory guidelines and requirements heavily regulate the manufacturing of our products, including manufacturing quality standards. Periodic inspections are conducted on our manufacturing sites, and if the regulatory and quality standards and systems are not found adequate, it could result in observations. This might impact our ability to meet demand and generate value for our stakeholders.	Creating a strong ethical organisational culture with a focus on transparency and Compliance. Regularly carrying out risk assessments and audits to identify areas of potential exposure to compliance related risks. Compliance training.	Negative Implications
5	Return on Equity/Return to Share holders	O	ROE reflects a company's profitability, financial health, and business resilience. Strong ROE helps a business attract investors, gain greater access to capital, and create value for stakeholders.	Increasing operational Efficiency. Exploring new market opportunities/products Strengthening corporate governance standards.	Positive Implications
6	Resource Efficiency	O	Focusing on how efficiently and effectively company uses natural resources and raw materials during its manufacturing and business activities.	Improve operational and manufacturing efficiency and also, attract environmentally conscious customers and reduce costs.	Positive Implications
7	Diversity, Equity and Inclusion	O	Promoting diversity, inclusion and equity in Company, and providing fair and equal remuneration and advancement opportunities to all employees. Ensuring there is no discrimination based on race, ethnicity, caste, colour, age, sex, disability, sexual orientation and the socioeconomic status of an individual	Ensuring diversity can enhance organizational performance because it brings together people with varying views and perspectives. This, in turn, leads to better talent attraction and retention, increases greater employee engagement and results in higher efficiency. The diversity also results in better innovation and problem-solving skills, and improves talent attraction.	Positive Implications

Notes

SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
Policy and management processes
1. a. Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No/NA)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

b. Has the policy been approved by the Board? (Yes/No/NA)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
b. Has the policy been approved by the Board? (Yes/No/NA)
c. Web Link of the Policies, if available	http://marksanspharma.com/codes-policies.html	http://marksanspharma.com/codes-policies.html	http://marksanspharma.com/codes-policies.html	http://marksanspharma.com/codes-policies.html	http://marksanspharma.com/codes-policies.html	http://marksanspharma.com/codes-policies.html	http://marksanspharma.com/codes-policies.html	http://marksanspharma.com/codes-policies.html	http://marksanspharma.com/codes-policies.html
2. Whether the entity has translated the policy into procedures. (Yes / No/ NA)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

3. Do the enlisted policies extend to your value chain partners? (Yes/No/NA)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

4. Name of the national and international codes/certifications/labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustee) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	NA	NA	NA	NA	NA	NA	NA	NA	NA
5. Specific commitments, goals and targets set by the entity with defined timelines, if any.
6. Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.
Governance, leadership and oversight
7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure)	Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements- Refer the Annual Report
8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).	Mr. Mark Saldanha (DIN: 00020983), Managing Director of the Company, oversees the BRSR implementation. Telephone No. 022 4001 2000, E-mail Id: companysecretary@marksanspharma.com
9. Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No/ NA).	Yes
If yes, provide details.	Mr. Mark Saldanha (DIN: 00020983), Managing Director of the Company, oversees the BRSR implementation. Telephone No. 022 4001 2000, E-mail Id: companysecretary@marksanspharma.com
10. Details of Review of NGRBCs by the Company
Indicate whether review was undertaken by Director/Committee of the Board/Any other Committee
Subject for Review	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	Director	Director	Director	Director	Director	Director	Director	Director	Director
Description of other committee for performance against above policies and follow up action
Compliance with statutory requirements of relevance to the principles and rectification of any non-compliances	Director	Director	Director	Director	Director	Director	Director	Director	Director
Description of other committee for compliance with statutory requirements of relevance to the principles and rectification
Frequency (Annually / Half yearly /Quarterly/ Any other-please specify)
	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	Annually	Annually	Annually	Annually	Annually	Annually	Annually	Annually	Annually
Description of other committee for performance against above policies and follow up action
Compliance with statutory requirements of relevance to the principles and rectification of any non-compliances	Annually	Annually	Annually	Annually	Annually	Annually	Annually	Annually	Annually
Description of other committee for compliance with statutory requirements of relevance to the principles and rectification
11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No).	P1	P2	P3	P4	P5	P6	P7	P8	P9
	false	false	false	false	false	false	false	false	false
If Yes, Provide name of the agency
12. If answer to question (1) above is 'No' i.e. not all Principles are covered by a policy, reasons to be stated:
Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the Principles material to its business (Yes/No)
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)
The entity does not have the financial or/human and technical resources available for the task (Yes/No)
It is planned to be done in the next financial year (Yes/No)
Any other reason (please specify)
Notes

SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as 'Essential' and 'Leadership'. While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.
PRINCIPLE 1 Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.
Essential Indicators
1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year:
Segment	Total number of training and awareness programmes held	Topics/principles covered under the training and its impact		%age of persons in respective category covered by the awareness programmes
Board of Directors	1	The Company conducts familiarization programmes for its Board of Directors on an annual basis covering Roles, Functions, Responsibilities and Duties.		100.00
Key Managerial Personnel	1	KMPs are imparted professional training through program conducted by respective professional bodies such as ICAI, ICSI. Also company conducts familiarization programs for its KMPs on an annual basis covering Roles, Functions, Responsibilities and Duties.		100.00
Employees other than BoD and KMPs	1	The Company conducts training programs for its employees at regular intervals covering Roles, Functions, Responsibilities and Duties.		100.00
Workers	1	The Company conducts training programs for its workers at regular intervals covering Roles, Functions, Responsibilities and Duties.		100.00
2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):
Monetary
Penalty/ Fine
Settlement
Compounding fee
Non- Monetary
Imprisonment
Punishment
3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed
4. Does the entity have anti-corruption or anti-bribery policy?	Yes
If Yes, provide details in brief	Marksans anti-bribery policy emphasizes on zero tolerance approach to bribery and corruption. The policy provides information and guidance on how to recognize and deal with bribery and corruption issues. It guides us to act professionally, fairly and with utmost integrity in all our business dealings and relationships, wherever we operate
Provide a web-link if the entity has anti-corruption or anti-bribery policy	https://www.marksanspharma.com/pdf/anti-corruption-policy.pdf
5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:
		FY (2023-24)		PY (2022-23)
Directors		0		0
KMPs		0		0
Employees		0		0
Workers		0		0
6. Details of complaints with regard to conflict of interest:
	FY (2023-24)		PY (2022-23)
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	0	NIL	0	NIL
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	0	NIL	0	NIL
7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.	Not Applicable
8. Number of days of accounts payables
		FY (2023-24)		PY (2022-23)
i) Accounts payable x 365 days		5,82,963.4		4,07,256.05
ii) Cost of goods/services procured		4,789.36		3,944.49
iii) Number of days of accounts payables		P122D		P103D
9. Open-ness of business - Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format
Parameter	Metrics	FY (2023-24)		PY (2022-23)
Concentration of Purchases	a. i) Purchases from trading houses	0		0
	ii) Total purchases	0		0
	iii) Purchases from trading houses as % of total purchases
	b. Number of trading houses where purchases are made	0		0
	c. i) Purchases from top 10 trading houses	0		0
	ii) Total purchases from trading houses	0		0
	iii) Purchases from top 10 trading houses as % of total purchases from trading houses
Parameter	Metrics	FY (2023-24)		PY (2022-23)
Concentration of Sales	a. i) Sales to dealer / distributors	1,067.44		951.36
	ii) Total Sales	8,532.73		6,552.04
	iii) Sales to dealer / distributors as % of total sales	12.51		14.52
	b. Number of dealers / distributors to whom sales are made	15		13
	c. i) Sales to top 10 dealers / distributors	768.9		671.73
	ii) Total Sales to dealer / distributors	1,025.21		895.65
	iii) Sales to top 10 dealers / distributors as % of total sales to dealer / distributors	75.00		75.00
Parameter	Metrics	FY (2023-24)		PY (2022-23)
Share of RPTs in	a. i) Purchases (Purchases with related parties)	0		0
	ii) Total Purchases	0		0
	iii) Purchases (Purchases with related parties as % of Total Purchases)
	b. i) . Sales (Sales to related parties)	6,945.33		5,443.73
	ii) Total Sales	8,532.73		6,552.04
	iii) Sales (Sales to related parties as % of Total Sales)	81.40		83.08
	c. i) Loans & advances given to related parties	0		0
	ii) Total loans & advances	0		0
	iii) Loans & advances given to related parties as % of Total loans & advances
	d. i) Investments in related parties	2,657.53		2,657.53
	ii) Total Investments made	2,657.53		2,657.53
	iii) Investments in related parties as % of Total Investments made	100.00		100.00
Leadership Indicators
1. Awareness programmes conducted for value chain partners on any of the Principles during the financial year
2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board?	Yes
If Yes, provide details of the same.	The Company has in place policies and procedures to ensure high level of governance and ethics, transparency and accountability in business transactions. The Company has also in place a whistle blower policy under which directors and employees can report their genuine concerns, actual or suspected fraud or violation of the Company's codes of conduct. The Company has also in place a comprehensive Code of Conduct for Directors and Senior Management. Every Board member discloses the names of the entities or arrangements in which they are interested which is brought to the attention of the Board. The Company does not enter into any business dealings with the Directors and KMPs, or any body or individuals, where they have interest that may have any potential conflict with the interest of the Company.
Notes

PRINCIPAL 2 Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

FY (2023-24)

PY (2022-23)

Details of improvements in environmental and social impacts

R&D

0.00

Capex

0.00

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)

true

b. If yes, what percentage of inputs were sourced sustainably?

51.00

3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for

(a) Plastics (including packaging)

The waste generated is given to the authorized scrap dealer.

(b) E-waste

E-waste generated is given to Authorized recycler.

Hazardous waste generated such as used / spent oil is given to the authorized recycler for recycling and the process waste & residue generated is sent to the authorized cement industry for co processing.

(d) other waste

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No).

true

If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards?

true

If not, provide steps taken to address the same.

Leadership Indicators

1. Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)?

4. Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed, as per the following format:

FY (2023-24)

PY (2022-23)

Re-Used

Recycled

Safely Disposed

Re-Used

Recycled

Safely Disposed

Plastics (including packaging)

25.49

23.5

E waste

1.09

0.1

Hazardous waste

0.7

449.91

1.8

409.6

Other waste

Details of other waste
Sr. No.	Name Of Other Waste	FY (2023-24)			PY (2022-23)
		Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed

Notes

In the pharmaceutical industry, we can't use recycled or reused input materials in the manufacturing process due to contamination issues as well as its nature of products.

PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators

1. a. Details of measures for the well-being of employees:

Category

% of employees covered by

Total (A)

Health insurance

Accident insurance

Maternity benefits

Paternity Benefits

Day Care facilities

Number (B)

% (B / A)

Number (C)

% (C / A)

Number (D)

% (D / A)

Number (E)

% (E / A)

Number (F)

% (F / A)

Permanent employees

Male

704

422

59.95

0.00

Female

111

40.55

0.00

111

100.00

0.00

Other

0.00

Total

815

467

57.31

0.00

111

13.62

0.00

Other than permanent employees

Male

0.00

Female

0.00

Other

0.00

Total

0.00

b. Details of measures for the well-being of workers:

Category

% of workers covered by

Total (A)

Health insurance

Accident insurance

Maternity benefits

Paternity Benefits

Day Care facilities

Number (B)

% (B / A)

Number (C)

% (C / A)

Number (D)

% (D / A)

Number (E)

% (E / A)

Number (F)

% (F / A)

Permanent workers

Male

326

100

30.68

0.00

Female

0.00

Other

0.00

Total

326

100

30.68

0.00

Other than permanent workers

Male

180

0.00

Female

0.00

Other

0.00

Total

277

0.00

C. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format:

FY (2023-24)

PY (2022-23)

i) Cost incurred on wellbeing measures (well-being measures means well-being of employees and workers (including male, female, permanent and other than permanent employees and workers)

6.21

4.77

ii) Total revenue of the company

9,153.46

7,156.86

iii) Cost incurred on wellbeing measures as a % of total revenue of the company

0.07

2. Details of retirement benefits

Benefits

FY (2023-24)

PY (2022-23)

No.of employees covered as a % of total employees

No.of workers covered as a % of total workers

Deducted and deposited with the authority (Y/N/N.A.)

No.of employees covered as a % of total employees

No.of workers covered as a % of total workers

Deducted and deposited with the authority (Y/N/N.A.)

100.00

Yes

100.00

Yes

Gratuity

100.00

Yes

100.00

Yes

ESI

29.00

44.00

Yes

48.00

84.00

Yes

Others - please specify

Details of Other Retirement benefits
Sr. No.	Name of Benefits	FY (2023-24)			PY (2022-23)
		No.of employees covered as a % of total employees	No.of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No.of employees covered as a % of total employees	No.of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)

3. Accessibility of workplaces

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes

If not, whether any steps are being taken by the entity in this regard.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016?

Yes

If so, provide a web-link to the policy.

https://www.marksanspharma.com/pdf/Code-of-Conduct.pdf

5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender

Permanent employees

Permanent workers

Return to work rate

Retention rate

Return to work rate

Retention rate

Male

100

Female

101

Other

102

Total

103

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker?

true

If yes, give details of the mechanism in brief.

Yes/No

(If Yes, then give details of the mechanism in brief)

Permanent Workers

true

The organization has a Whistle Blower policy in place which provides all employees and workers an opportunity to raise any issues/grievances anonymously, where the identity of the whistleblower is kept confidential. A dedicated email ID has been created at an organizational level, to which the employee and workers can write their concerns. A dedicated single point contact (SPOC) is assigned to look into all matters independently and fairly. Marksans Pharma has established a well-placed process for addressing employee grievances. An employee with a grievance can reach out to his immediate manager or skip manager as the first point of contact. In case of no resolution, the respective business HR is the next point of contact, responsible for investigation and resolution in a fair & transparent manner. For POSH-related matters, the employee is expected to raise it with the HR team or to the dedicated email ID for Internal Committee. This can be escalated to the Chairperson of the Internal Committee. The final level of escalation is to the HR Head of the organization

Other than Permanent Workers

true

Permanent Employees

true

Other than Permanent Employees

true

7. Membership of employees and worker in association(s) or Unions recognised by the listed entity:

Category

FY (2023-24)

PY (2022-23)

Total employees/workers in respective category (A)

No.of employees / workers in respective category, who are part of association(s) or Union (B)

% (B / A)

Total employees / workers in respective category (C)

No.of employees /workers in respective category,who are part of association(s) or Union (D)

% (D / C)

Total Permanent Employees

815

0.00

572

0.00

Male

704

0.00

493

0.00

Female

111

0.00

Other

0.00

Total Permanent Workers

326

27.61

280

118

42.15

Male

326

27.61

280

118

42.15

Female

0.00

Other

0.00

8. Details of training given to employees and workers:

Category

FY (2023-24)

PY (2022-23)

Total (A)

On Health and safety measures

On Skill upgradation

Total (D)

On Health and safety measures

On Skill upgradation

No.(B)

% (B / A)

No.(C)

% (C / A)

No.(E)

% (E / D)

No. (F)

% (F / D)

Employees

Male

704

100.00

0.00

493

143

29.01

0.00

Female

111

100.00

0.00

59.50

0.00

Other

0.00

Total

815

100.00

0.00

572

190

33.22

0.00

Workers

Male

326

100.00

0.00

280

100.00

0.00

Female

0.00

Other

0.00

Total

326

100.00

0.00

280

100.00

0.00

9. Details of performance and career development reviews of employees and worker:

Category

FY (2023-24)

PY (2022-23)

Total (A)

No.(B)

% (B / A)

Total (D)

No.(E)

% (E / D)

Employees

Male

704

100.00

493

100.00

Female

111

100.00

Other

0.00

Total

815

100.00

572

100.00

Workers

Male

326

100.00

280

100.00

Female

0.00

Other

0.00

Total

326

100.00

280

100.00

10. Health and safety management system:

a.Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No/ NA).

Yes

If yes, the coverage such system?

The Company has Occupational Health and Safety Management system implemented at our site covering the following but not limited to: 1. Occupational Safety and Health Policy 2. OS&H Organizational Setup 3. Education and Training 4. Employee Participation in OS&H Management 5. Motivational and Promotional Measures for OS&H 6. Safety Manual and Rules 7. Compliance of Statutory Requirements 8. Accident reporting, analysis, investigation and implementation of recommendation. 9. Risk Assessment including Hazard Identification 10. Safety inspections 11. First aid facility - Occupational Health Centre 12. Personal Protective Equipment 13. Ventilation, Illumination and Noise 14. Work Permit System 15. Fire Prevention, Protection and Fighting System 16. Hazardous waste Treatment and Disposal 17. Emergency Preparedness Plans

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

The Company has a process for Risk Management which is essential for preventing incidents, injuries, occupational disease, emergency preparedness and business continuity. There is a structured Risk Assessment and Management process which is regularly reviewed and mitigation plans are put in place to reduce the risk. For all the activities including routine or non-routine,hazards are identified by a trained cross functional team and risk assessment is done through standard operating procedures (SOP) which is referred before starting any activity. Identified hazards and associated risks are addressed through operational control measure using hierarchy of control approach.

c. Whether you have processes for workers to report the work related hazards and to remove themselves from such risks?

Yes

d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services?

Yes

11. Details of safety related incidents, in the following format:

Safety Incident/Number

Category*

FY (2023-24)

PY (2022-23)

Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)

Employees

Workers

Total recordable work-related injuries

Employees

Workers

No. of fatalities

Employees

Workers

High consequence work related injury or ill-health (excluding fatalities)

Employees

Workers

12. Describe the measures taken by the entity to ensure a safe and healthy work place.

The Company undertakes periodic internal and external audits to assess the safety practices and procedures. The Company endeavors to prevent negative health impact on the employees through provision of medical facilities and medical insurance benefits.

13. Number of Complaints on the following made by employees and workers:

FY (2023-24)

PY (2022-23)

Filed during the year

Pending resolution at the end of year

Remarks

Filed during the year

Pending resolution at the end of year

Remarks

Working Conditions

Health & Safety

14. Assessments for the year:

% of your plants and offices that were assessed (by entity or statutory authorities or third parties)

Health and safety practices

100.00

Working Conditions

100.00

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

Not Applicable

Leadership Indicators

1. Does the entity extend any life insurance or any compensatory package in the event of death of

(A) Employees (Y/N)

true

(B) Workers (Y/N).

true

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.

Submission, review and checking of the monthly statutory dues deducted and deposited by the value chain partner. For value chain partners we are conducting monthly audit & verified statutory registers such as wage register, muster-roll, online challan, etc.

3. Provide the number of employees / workers having suffered high consequence work related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

Total no. of affected employees/ workers

No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment

FY (2023-24)

PY (2022-23)

FY (2023-24)

PY (2022-23)

Employees

Workers

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No/ NA)

Yes

5. Details on assessment of value chain partners:

% of value chain partners (by value of business done with such partners) that were assessed

Health and safety practices

0.00

Working Conditions

0.00

6. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners.

Currently, the Company does not have any significant risks/concerns arising from assessments of health and safety practices and working conditions of value chain partners.

Notes

PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders

Essential Indicators

1. Describe the processes for identifying key stakeholder groups of the entity.

Marksans Pharma believes in partnering with its various stakeholders to build shared value and uses a structured approach of stakeholder identification. The Company's stakeholders include both individuals and organizations, within and outside the Company, who are significantly impacted by its business operations. Marksans ongoing engagements are designed to determine the needs and priorities of stakeholders, communicate the Company's efforts to fulfill their expectations, and provide speedy resolution of grievances. Marksans uses a variety of structured engagement channels to gain insights into stakeholder views and concerns.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Sr. No.	Stakeholder Group	Whether identified as Vulnerable & Marginalized Group	Channels of communication	Details of Other Channels of communication	Frequency of engagement	Details of Other Frequency of engagement	Purpose and scope of engagement including key topics and concerns raised during such engagement
1	Employees and workers	false	E-mail		Others - please specify	Monthly, quarterly and need based	Talent management, Employee engagement, Learning and development, Productivity Work-life balance, Staff welfare and Health & Safety, Remuneration and employee benefits
2	Suppliers	false	E-mail		Quarterly		Fair contractual terms and adherence thereto, Organizational ESG consciousness, Transparent, ethical and long term business relations, Regular exchange of technical know-how
3	Distributors	false	E-mail		Quarterly		As per prevalent need
4	End Customers	true	E-mail		Quarterly		Effective customer grievance redressal mechanism, Maintaining customer data privacy and security, Suitability of products and service, Transparent and fair advice, Providing quality products
5	Shareholders	false	Website		Quarterly		Market outlook, Business strategy, Operational efficiency, Long-term business performance, ESG/Market risks and opportunities in business Technology in business
6	Regulators	false	E-mail		Others - please specify	Need based	Compliance with rules and regulations Corporate governance framework Long-term business performance, Financial performance, Prudent business practices

Leadership Indicators

1. Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.

The Company has always maintained a constant and proactive engagement with our key stakeholders that enables the Company to better communicate its strategies and performance. A continuous engagement helps align expectations, thereby enabling the Company to better serve its stakeholders. The Board is kept abreast on various developments and feedback on the same is sought from the Directors.

2.Whether stakeholder consultation is used to support the identification and management of environmental, and social topics.

true

If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.

Marksans Pharma has established channels for active engagement with all stakeholder groups. It is through this continued practice that the Company is offering competitive edge with the brand trust. We interact with critical stakeholders on a regular basis to ensure that our business is aligned with the stakeholder interests in a sustainable manner while being a profitable proposition. Based on such discussions with the investment community, we have aligned our goals on environmental management and amended our Policies and internal systems for environmental management.

3. Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.

Marksans Pharma has fostered an active engagement channel with end customers for addressing any grievances relating to our products and assisting them in every way possible.

Notes

PRINCIPLE 5 Businesses should respect and promote human rights

Essential Indicators
1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:
Category	FY (2023-24)						PY (2022-23)
	Total (A)		No. of employees/workers covered (B)		% (B / A)		Total (C)		No. of employees/workers covered (D)	% (D / C)
Employees
Permanent	815		815		100.00		572		572	100.00
Other than permanent	0		0		0.00		0		0	0.00
Total Employees	815		815		100.00		572		572	100.00
Workers
Permanent	326		326		100.00		280		280	100.00
Other than permanent	277		277		100.00		221		221	100.00
Total Workers	603		603		100.00		501		501	100.00
2. Details of minimum wages paid to employees and workers, in the following format:
Category	FY (2023-24)					PY (2022-23)
	Total (A)	Equal to Minimum Wage		More than Minimum Wage		Total (D)	Equal to Minimum Wage		More than Minimum Wage
		No.(B)	% (B /A)	No.(C)	% (C /A)		No.(E)	% (E /D)	No.(F)	% (F /D)
Employees
Permanent	815	99	12.15	720	88.35	572	102	17.84	470	82.17
Male	704	84	11.94	624	88.64	493	79	16.03	414	83.98
Female	111	15	13.52	96	86.49	79	23	29.12	56	70.89
Other	0	0	0.00	0	0.00	0	0	0.00	0	0.00
Other than Permanent	0	0	0.00	0	0.00	0	0	0.00	0	0.00
Male	0	0	0.00	0	0.00	0	0	0.00	0	0.00
Female	0	0	0.00	0	0.00	0	0	0.00	0	0.00
Other	0	0	0.00	0	0.00	0	0	0.00	0	0.00
Workers
Permanent	326	71	21.78	225	69.02	280	231	82.50	49	17.50
Male	326	71	21.78	225	69.02	280	231	82.50	49	17.50
Female	0	0	0.00	0	0.00	0	0	0.00	0	0.00
Other	0	0	0.00	0	0.00	0	0	0.00	0	0.00
Other than Permanent	277	277	100.00	0	0.00	221	221	100.00	0	0.00
Male	180	180	100.00	0	0.00	139	139	100.00	0	0.00
Female	97	97	100.00	0	0.00	82	82	100.00	0	0.00
Other	0	0	0.00	0	0.00	0	0	0.00	0	0.00
3. Details of remuneration/salary/wages, in the following format:
a. Median remuneration / wages:
	Male				Female				Other
	Number		Median remuneration/ salary/ wages of respective category		Number		Median remuneration/ salary/ wages of respective category		Number	Median remuneration/ salary/ wages of respective category
Board of Directors (BoD)	2		4,38,03,441		1		70,69,164		0	0
Key Managerial Personnel	2		78,43,247		0		0		0	0
Employees other than BoD and KMP	799		2,21,079		159		2,21,818		0	0
Workers	510		2,05,537		2		1,34,837		0	0
b. Gross wages paid to females:
	FY (2023-24)					PY (2022-23)
Gross wages paid to females	6,23,86,211.55					4,19,04,292.4
Total wages	70,79,39,332					51,12,63,044
Gross wages paid to females (Gross wages paid to females as % of total wages)	8.81					8.20
4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business?	true
5. Describe the internal mechanisms in place to redress grievances related to human rights issues.	The Organization has multiple policies and platforms to address the employee grievances related to human rights. These are as under: i. Human Resource (HR) Assistance: Every geography/business facility of the Company has a dedicated HR personnel who can be reached out by respective employees to raise any concerns or grievances with respect to any human rights issue, or otherwise. In case the issue remains unresolved, an escalation matrix is defined to enable employees to reach out to next level authorities ii. Whistle Blower (WB) Policy: The organization has a WB policy in place which provides all employees to an option and opportunity to raise any issues/grievances anonymously, where the identity of the whistle blower is kept confidential. iii. Prevention of Sexual Harassment Guidelines (POSH): With an aim to provide a safe and equal opportunity to both the genders, the organization has in place the guidelines for POSH. The Organization aims to create awareness from time to time so that any untoward situation of harassment is witnessed, one can reach out to the Internal Committee of the Organization. Employees can also reach out to the HR team alternatively to report the matter. An Internal committee is formed for each reported instance as prescribed by POSH Act to conduct investigation and take necessary action, as and when required.
6. Number of Complaints on the following made by employees and workers:
	FY (2023-24)						PY (2022-23)
	Filed during the year		Pending resolution at the end of year		Remarks		Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	0		0				0	0
Discrimination at workplace	0		0				0	0
Child Labour	0		0				0	0
Forced Labour/Involuntary Labour	0		0				0	0
Wages	0		0				0	0
Other human rights related issues	0		0				0	0
7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:
	FY (2023-24)					PY (2022-23)
i) Total Complaints reported under Sexual Harassment on of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	0					0
ii) Female employees / workers	0					0
iii) Complaints on POSH as a % of female employees / workers
iv) Complaints on POSH upheld	0					0
8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.	To safeguard the complainant against any adverse consequences, Company maintains utmost confidentiality of the Complainant. All related parties against whom the Complaint has been reported are sensitized of any retaliatory action against the complainant. In case of any incident of retaliation, Company will take appropriate action on the reported matter and ensures that the complainant does not undergo adverse consequences.
9. Do human rights requirements form part of your business agreements and contracts? (Yes/No/NA)	No
10. Assessments for the year:
	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100.00
Forced/involuntary labour	100.00
Sexual harassment	100.00
Discrimination at workplace	100.00
Wages	100.00
11. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above.	NA
Leadership Indicators
1. Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints.	No significant complaints were substantiated
2. Details of the scope and coverage of any Human rights due-diligence conducted	At present, no such exercise has been conducted in the reporting period.
3. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?	true
4. Details on assessment of value chain partners:
	% of value chain partners (by value of business done with such partners) that were assessed
Sexual harassment	0.00
Discrimination at workplace	0.00
Child Labour	0.00
Forced Labour/Involuntary Labour	0.00
Wages	0.00
5. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above.	Not Applicable
Notes

PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment

Essential Indicators

1. Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:

Whether total energy consumption and energy intensity is applicable to the company?

true

Revenue from operations (in Rs.)

FY (2023-24)

PY (2022-23)

8,532.73

6,552.04

Parameter

Units

FY (2023-24)

PY (2022-23)

From renewable sources

Total electricity consumption (A)

Megajoule (MJ)

Total fuel consumption (B)

Megajoule (MJ)

Energy consumption through other sources (C)

Megajoule (MJ)

Details of Energy consumed from renewable
Sr. No.	Name of other parameter	Unit	FY (2023-24)	PY (2022-23)

Total energy consumed from renewable sources (A+B+C)

Megajoule (MJ)

From non-renewable sources

Total electricity consumption (D)

Megajoule (MJ)

62917854.12

49883353.2

Total fuel consumption (E)

Megajoule (MJ)

19391058

9742478

Energy consumption through other sources (F)

Megajoule (MJ)

Details of Energy consumed from non renewable
Sr. No.	Name of other parameter	Unit	FY (2023-24)	PY (2022-23)

Total energy consumed from non-renewable sources (D+E+F)

Megajoule (MJ)

82308912.12

59625831.2

Total energy consumed (A+B+C+D+E+F)

Megajoule (MJ)

82308912.12

59625831.2

Energy intensity per rupee of turnover (Total energy consumed / Revenue from operations)

Megajoule (MJ) / Rs.

9646.2576596236

9100.3460296335

Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)(Total energy consumed / Revenue from operations adjusted for PPP)

Megajoule (MJ) / Rs.

2.16

0.2

Energy intensity in terms of physical Output

Megajoule (MJ)

11733.1

9465.56

Energy intensity (optional) - the relevant metric may be selected by the entity

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

false

If yes, name of the external agency.

2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India?

false

If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.

3. Provide details of the following disclosures related to water, in the following format:

Parameter

FY (2023-24)

PY (2022-23)

Water withdrawal by source (in kilolitres)

(i) Surface water

(ii) Groundwater

946

147

(iii) Third party water

77441.66

89628

(iv) Seawater / desalinated water

(v) Others

Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)

78387.66

89775

Total volume of water consumption (in kilolitres)

78387.66

89775

Water intensity per rupee of turnover (Total water consumption / Revenue from operations)

9.1867034349

13.7018394271

Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)(Total water consumption / Revenue from operations adjusted for PPP)

205.7664

303.729

Water intensity in terms of physical output

11.17

14.25

Water intensity (optional) - the relevant metric may be selected by the entity

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency?

false

If yes, name of the external agency.

4. Provide the following details related to water discharged:

Parameter

FY (2023-24)

PY (2022-23)

Water discharge by destination and level of treatment (in kilolitres)

(i) To Surface water

24292

27649

No treatment

With treatment - please specify level of treatment

24292

27649

(ii) To Groundwater

No treatment

With treatment - please specify level of treatment

(iii) To Seawater

No treatment

With treatment - please specify level of treatment

(iv) Sent to third-parties

No treatment

With treatment - please specify level of treatment

(v) Others

No treatment

With treatment - please specify level of treatment

Total water discharged (in kilolitres)

24292

27649

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

false

If yes, name of the external agency.

5. Has the entity implemented a mechanism for Zero Liquid Discharge?

Yes

If yes, provide details of its coverage and implementation.

The ETP treated water is used for Gardening purpose.

6. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Whether air emissions (other than GHG emissions) by the entity is applicable to the company?

true

Parameter

Please specify unit

FY (2023-24)

PY (2022-23)

NOx

Kg/Day

0.22

0.25

SOx

0.22

0.36

Particulate matter (PM)

Kg/Day

0.15

0.14

Persistent organic pollutants (POP)

Kg/Day

Volatile organic compounds (VOC)

Kg/Day

Hazardous air pollutants (HAP)

Kg/Day

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

true

If yes, name of the external agency.

M/s. Sadekar Enviro Engineering Pvt. Ltd

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Whether greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity is applicable to the company?

true

Parameter

Unit

FY (2023-24)

PY (2022-23)

Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)

MtCO2e

23130.25

22110.22

Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)

MtCO2e

Total Scope 1 and Scope 2 emission intensity per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)

MtCO2e / Rs.

2.7107678316

3.3745551004

Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)

MtCO2e / Rs.

60.7212

74.8138

Total Scope 1 and Scope 2 emission intensity in terms of physical output

MtCO2e

3.29

3.5

Total Scope 1 and Scope 2 emission intensity (optional) - the relevant metric may be selected by the entity

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

false

If yes, name of the external agency.

8. Does the entity have any project related to reducing Green House Gas emission?

Yes

If Yes, then provide details.

We have energy management policy in place and we monitor the targets annually.

9. Provide details related to waste management by the entity, in the following format:

Parameter

FY (2023-24)

PY (2022-23)

Total Waste generated (in metric tonnes)

Plastic waste (A)

27.63

23.47

E-waste (B)

1.092

0.11

Bio-medical waste (C)

Construction and demolition waste (D)

Battery waste (E)

Radioactive waste (F)

Other Hazardous waste. Please specify, if any. (G)

Other Non-hazardous waste generated (H). Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector)

Total (A + B + C + D + E + F + G + H)

28.722

23.58

Waste intensity per rupee of turnover (Total waste generated / Revenue from operations)

0.0033660974

0.0035988791

Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total waste generated / Revenue from operations adjusted for PPP)

0.075

0.079

Waste intensity in terms of physical output

0.00401

0.003745

Waste intensity (optional) - the relevant metric may be selected by the entity

For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)

Category of waste

(i) Recycled

15.199

0.117

(ii) Re-used

(iii) Other recovery operations

Total

15.199

0.117

For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)

Category of waste

(i) Incineration

(ii) Landfilling

(iii) Other disposal operations

449.907

409.649

Total

449.907

409.649

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

true

If yes, name of the external agency.

Hazardous Waste Management Systems

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

Hazardous Waste disposal is done through GSPCB Authorized vendor as per the Environment protection act 1986 guidelines. A manifest system (form 10 and form 9) as per rule 19 for disposal of Hazardous waste is endorsed by dispatcher, transporter and receiver of hazardous waste. The endorsed copy is submitted to GSPCB on official website

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N/NA).

Yes

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

false

If yes, name of the external agency.

2. Please provide details of total Scope 3 emissions & its intensity, in the following format:

Whether total Scope 3 emissions & its intensity is applicable to the company?

false

Parameter

Unit

FY (2023-24)

PY (2022-23)

Total Scope 3 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)

Total Scope 3 emissions per rupee of turnover

Total Scope 3 emission intensity (optional) - the relevant metric may be selected by the entity

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

If yes, name of the external agency.

3. With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.

Not Applicable

4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives
Sr. No.	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative	Corrective action taken, if any
1	Upgradation & Separation of existing STP from ETP	Presently the ETP and STP are clubbed as a one unit, but below problems are encountered. 1) Final treated / Recycled Water is not clear and remains turbid, though the Ph and other parameters are within limits. 2) Due to mixing of Effluents and Sewage, water biomass increases and remains on higher side @70% (Limit is 30 to 40%) thus increasing the load and more consumption of treatment chemicals. 3) Increased power consumption	1) Cost of chemicals used for treatment will be reduced. 2) Savings in power bills. 3) Hazardous Sludge will be reduced reducing the disposal cost. 4) Saving in cost of additional tanker requirement for disposing of the excess effluents. 5) Biomass of ETP water will be maintained within limits. 6) Quality of treated water will be improved. 7) Requirement of additional tanker to dispose off the excess effluents will be eliminated	NIL

5. Does the entity have a business continuity and disaster management plan?

Yes

Details of entity at which business continuity and disaster management plan is placed or weblink.

Marksans Business Continuity plan is the creation of a plan to resume its critical business processes after a disruption. The goal of the plan is to prevent loss of life, reduce property damage and minimise the impact on the overall business functions. The overall objective of the plan is to provide the information and procedures necessary to rapidly respond to a disaster or emergency situation, notify necessary trained personnel, assemble business recovery teams, rapidly recover services to clients, and to rapidly resume normal business functions.

6. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.

None

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

0.00

Notes

PRINCIPLE 7 Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

Essential Indicators
1. a. Number of affiliations with trade and industry chambers/ associations.	1
b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to
Sr. No.	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/National/International)
1	Bombay Chamber of Commerce	National
Leadership Indicators
Notes

PRINCIPLE 8 Businesses should promote inclusive growth and equitable development

Essential Indicators

3. Describe the mechanisms to receive and redress grievances of the community.

The Company engages with its community members through in-person meetings

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:

FY (2023-24)

PY (2022-23)

Directly sourced from MSMEs/ small producers

6.17

12.90

Sourced directly from within the district and neighbouring districts

69.04

60.72

5. Job creation in smaller towns - Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost:

FY (2023-24)

PY (2022-23)

1.Rural

i) Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis)

ii) Total Wage Cost

iii) % of Job creation in Rural areas

2.Semi-urban

i) Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis)

ii) Total Wage Cost

iii) % of Job creation in Semi-urban areas

3.Urban

i) Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis)

49,04,54,209.4

31,86,36,034.7

ii) Total Wage Cost

70,79,39,332

51,12,63,044

iii) % of Job creation in Urban areas

69.28

62.32

4.Metropolitan

i) Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis)

21,74,85,122.6

19,26,27,009.4

ii) Total Wage Cost

70,79,39,332

51,12,63,044

iii) % of Job creation in Metropolitan areas

30.72

37.68

Leadership Indicators

3. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No/NA)

(b) From which marginalized /vulnerable groups do you procure?

0.00

6. Details of beneficiaries of CSR Projects:

Details of beneficiaries of CSR Projects
Sr. No.	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized groups
1	Organized free health check-up camps and distributed free medicines and other medical supplies to under privileged people in the state of Goa	0	0.00
2	Medical treatment to under privileged society suffering from cancer and other blood disorders	1	0.00
3	Construction of New Building for Government Aided Nursing Institute	0	0.00
4	Distribution of free food items to needy people.	0	0.00
5	Tree plantation in Verna Industrial Estate, Goa	0	0.00
6	Providing Sanitary Pads to poor women under the "MY PAD, MY RIGHT" program, an initiative of Swatch Bharat scheme of Beti Bachao scheme of the Govt. of India, under the Ministry of Women & Child Development and Skill Development	0	0.00
7	Donations to Reginaldo Trust for improving services in farming sector by giving medical equipments and facilitating better access to e-learning and online services to needy people.	0	0.00
8	Women and child development, professionalizing Anganwadis and national nutrition mission in Goa	0	0.00
9	Donations towards construction of new school building to Chetna Charitable trust	0	0.00
10	Desktop Distributed to underprivileged student of Satguru Foundation in Kudaim, Goa	0	0.00

Notes

PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators
1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.	Every endeavor is made to achieve maximum customer satisfaction by manufacturing world class quality product and ensuring fair treatment in all customer dealings. The Company complies with all applicable labeling standards. Customer's complaints are attended on priority basis. There is no customer complaints/ consumer cases pending resolutions at the end of the financial year. There is no case against the Company regarding unfair trade practice, irresponsible advertising, anti-competitive behavior during the last five years. The Company carries out consumer survey periodically.
2. Turnover of products and/ services as a percentage of turnover from all products/service that carry information about	As a percentage to total turnover
Environmental and social parameters relevant to the product	100.00
Safe and responsible usage	100.00
Recycling and/or safe disposal	100.00
3. Number of consumer complaints in respect of the following	FY (2023-24)		Remark	PY (2022-23)		Remark
	Received during the year	Pending resolution at end of year		Received during the year	Pending resolution at end of year
Data privacy	0	0	NIL	0	0	NIL
Advertising	0	0	NIL	0	0	NIL
Cyber-security	0	0	NIL	0	0	NIL
Delivery of essential services	0	0	NIL	0	0	NIL
Restrictive Trade Practices	0	0	NIL	0	0	NIL
Unfair Trade Practices	0	0	NIL	0	0	NIL
Other	0	0	NIL	0	0	NIL
4. Details of instances of product recalls on account of safety issues	Number			Reasons for recall
Voluntary recalls	0			NA
Forced recalls	0			NA
5. Does the entity have a framework/ policy on cyber security and risks related to data privacy?	Yes
If available, provide a web-link of the policy	https://www.marksanspharma.com/pdf/risk-management-policy.pdf
6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.	None
7. Provide the following information relating to data breaches:
a. Number of instances of data breaches along-with impact	0
b. Percentage of data breaches involving personally identifiable information of customers	0.00
c. Impact, if any, of the data breaches	NA
Leadership Indicators
1. Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available).	www.marksanspharma.com
2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services	At Marksans, sustainable innovation is a core part of Company's DNA. The Company continues to work together with our partners and customers to explore new ways to incorporate sustainable materials across our product range and bring them to new markets including increased communications. The Company carries out consumer survey periodically.
3. Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.	Issues that are bound to arise in any customer/supplier relationship, there is continual communication maintained with customers. This helps to identify problems before they become serious and allows both the parties to work towards mutually beneficial solutions. The Company focuses on quality and customer service and continues to strengthen our relationship and position as a trusted partner.
4. Does the entity display product information on the product over and above what is mandated as per local laws?	No
If yes, provide details in brief.
Did your entity carry out any survey with regard to consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole?	Yes
Notes